Yuekang Pharmaceutical (688658.SH): Injection YKYY031 approved for conducting late-stage solid tumor clinical trials.

Wisdom Financial News APP News, Yuekang Pharmaceutical (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) for the approval of the use of YKYY031 for the treatment of advanced solid tumors.